8-K: Foghorn Therapeutics Halts FHD-909 Trial, Cuts Workforce

Foghorn Therapeutics and Eli Lilly have decided not to advance the Phase 1 trial of FHD-909 into the expansion phase, leading to a strategic reprioritization and a workforce reduction of approximately 40%.

Summary

• Foghorn Therapeutics and Eli Lilly have mutually decided not to proceed with the expansion phase of the Phase 1 clinical trial for FHD-909, citing insufficient efficacy despite a favorable safety profile.
• Consequently, further collaboration activities between Foghorn and Lilly are not anticipated, including the Selective SMARCA2 degrader program.
• Foghorn is undergoing a strategic reprioritization and workforce reduction of approximately 40%, aiming to focus resources on its proprietary pipeline.
• The company expects to incur aggregate charges of approximately $2.3 million related to these changes, primarily for severance and benefit costs, anticipated in the fourth quarter of 2026.
• Following the workforce reduction, Foghorn anticipates having approximately 65 full-time employees.
• The company's cash runway is expected to be extended into the second half of 2029 due to these strategic adjustments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the discontinuation of a key clinical trial and significant workforce reduction, impacting future growth prospects.

Positives

• FHD-909 demonstrated a favorable safety profile at exposures exceeding preclinical targets.
• The company's proprietary pipeline, including selective EP300 degrader, immunology and inflammation asset, selective CBP degrader, and induced proximity platform, will receive focused resources.
• The strategic reprioritization and workforce reduction are expected to extend the company's cash runway into the second half of 2029.
• The company has a demonstrated capability in designing drugs for challenging molecular targets.

Negatives

• The clinical results for FHD-909 did not translate into the level of efficacy required for further advancement.
• The collaboration with Eli Lilly on the FHD-909 program and the Selective SMARCA2 degrader program will not advance.
• A workforce reduction of approximately 40% is being implemented, impacting a significant portion of the company's employees.
• The company will incur approximately $2.3 million in charges related to the workforce reduction and strategic changes.

Risks

• The workforce reduction may be larger than currently anticipated.
• The company may incur additional costs not currently contemplated.
• Risks identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings.

Future Outlook

The company is reprioritizing resources towards its proprietary pipeline, including its selective EP300 degrader, novel oral immunology and inflammation program, selective CBP degrader, and induced proximity platform, with the aim of extending its cash runway into the second half of 2029.

Management Comments

• "While we are disappointed with the clinical results, we and Lilly developed a drug in FHD-909 that selectively hits the SMARCA2 target with a favorable safety profile at exposures that exceeded our preclinical targets. Unfortunately, the biology of the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program."
• "We built Foghorn based on a demonstrated capability in designing drugs for challenging molecular targets, and we have leveraged this capability to build a proprietary pipeline. Today, we are committed to focusing our financial and developmental resources to advance these programs toward the clinic."
• "I would like to thank our partner Lilly for their support, as well as the patients, caregivers, investigators, study site staff, and all others who participated in and contributed to the FHD-909 clinical trial."

Industry Context

StockSavvy.ai notes that the discontinuation of the FHD-909 trial and subsequent strategic shift by Foghorn Therapeutics reflects the high-risk, high-reward nature of early-stage drug development, particularly in complex areas like chromatin regulation. The decision to focus on wholly-owned assets and reduce workforce is a common strategy for biotech firms facing clinical setbacks to preserve capital and extend runway.

Stakeholder Impact

• Shareholders: Potential negative impact due to trial discontinuation and workforce reduction, but positive impact from extended cash runway.
• Employees: Significant negative impact due to approximately 40% workforce reduction.
• Partners (Eli Lilly): Discontinuation of collaboration on specific programs.

Next Steps

• Focus resources on proprietary pipeline programs: selective EP300 degrader, novel oral immunology and inflammation program, selective CBP degrader, and induced proximity platform.
• Substantially complete workforce reduction in the fourth quarter of 2026.
• Continue to develop product candidates in oncology and in immunology & inflammation.

Key Dates

Recommendation

The decision to halt the FHD-909 trial and reduce the workforce is a significant negative event. However, the company's focus on its proprietary pipeline and the extended cash runway into 2029 provide some stability. A 'hold' recommendation reflects the uncertainty and risk associated with the reprioritized pipeline, balanced against the company's continued operational runway.

Keywords

FHD-909, Foghorn Therapeutics, Eli Lilly, clinical trial, drug development, oncology, immunology, biotechnology